nav-left cat-right
cat-right

Agilux Laboratories Hires New Associate Director to Lead In Vitro ADMET Services Division

- Adrian Sheldon, Ph.D., Positions Contract Research Organization for Growth -
WORCESTER, Mass.--(Business Wire)--
Agilux Laboratories, Inc., a Contract Research Organization (CRO) that provides
bioanalytical and in vitro Absorption Distribution Metabolism Excretion
Toxicology (ADMET) services for the biotechnology and pharmaceutical industries,
has appointed Dr. Adrian Sheldon as associate director of In Vitro ADMET
Services. In this role, Dr. Sheldon will build the In Vitro ADMET Services
division offering testing services that allow biotechnology and pharmaceutical
companies to screen drug candidates for desirable ADMET properties. Dr. Sheldon
will leverage more than 17 years of industry experience, including establishing
new business units for In Vitro ADMET and Immunochemistry within an established
CRO. He will extend Agilux`s emphasis on customer service, rapid turnaround and
exceptional data quality to the company`s newly formed In Vitro ADMET Services
Testing Division.

"We are excited to have someone with Adrian`s expertise, successful track record
and demonstrated abilities at Agilux," said Jim Jersey, president and CEO at
Agilux. "Adrian brings the right balance of scientific expertise and customer
focus, which is consistent with Agilux`s mission of delivering high quality data
at unprecedented speeds. We are confident that both the Agilux team and our
clients will benefit from his unique skill set."

Prior to Agilux, Dr. Sheldon served as associate director of In Vitro ADMET at
Charles River Laboratories. Prior to Charles River Laboratories, Dr. Sheldon was
group leader in Assay Development/HTS/In Vitro ADMET at ArQule where he
co-managed a team responsible for screening compounds generated by the
industry-leading combinatorial chemistry laboratory. He received his Ph.D. from
Boston University and his A.B. from Harvard University. Dr. Sheldon has authored
numerous scientific publications and holds two patents.

"I am very pleased about joining the team at Agilux," stated Dr. Sheldon. "We
have an incredible opportunity to change the way early stage development
services are delivered and I am confident that I will be able to contribute to
Agilux`s continuing success."

About Agilux Laboratories, Inc.

Agilux Laboratories, Inc. is a privately held contract research organization
(CRO) focused on bioanlaytical and PK/PD testing services for the biotech and
pharmaceutical industries. Leveraging industry and contract research experience
of its management team, the company delivers high quality bioanlaytical
chemistry and PK/PD data more rapidly. Agilux helps clients make better
decisions during drug discovery and development by providing quality data
earlier in the research process by using technologies and systems that increase
turnaround speed well beyond industry standards. Founded in 2007 by industry
experts Jim Jersey, Steve Guyan and Peter Glick, Agilux is headquartered in
Worcester, MA and is funded by private equity firm, Ampersand Ventures. For more
information, call 508-753-5000 or email sguyan@agiliuxlabs.com. Online at
www.agiluxlabs.com.



Agilux Laboratories, Inc.
Steve Guyan
Vice President, Sales and Marketing
508-762-4402
sguyan@agiluxlabs.com
Source: Reuters